MEDICAL WEIGHT MANAGEMENT – PHASE 3 STUDIES EQUIP AND CONQUER

CONQUER: A 56-week randomized, placebo-controlled study that evaluated the safety and efficacy of phentermine/topiramate for weight loss and metabolic improvements. The study included men and women with overweight or obese adults, with a body-mass index of 27–45 kg/m² and two or more comorbidities (hypertension, dyslipidaemia, diabetes or prediabetes, or abdominal obesity) who were randomized to once daily oral, placebo, phentermine/topiramate 7.5/46 mg, or phentermine/topiramate 15/92 mg as an adjunct to a reduced-energy diet and
physical activity.

EQUIP: A 56-week randomized, placebo-controlled study that evaluated the safety and efficacy of phentermine/topiramate for weight loss and metabolic improvements. The study included men and women with class II and III obesity (BMI ≥ 35 kg/m²) who were randomized to once daily, oral, placebo, phentermine/topiramate 3.75/23 mg, or phentermine/topiramate 15/92 mg as an adjunct to a reduced-energy diet and physical activity.